Autoantibodies and scleroderma risk study

This study tests whether blocking a protein called TL1A can help reduce skin thickening and improve the immune system in people with systemic sclerosis (a condition where skin becomes hard and thick). Researchers will compare skin and blood samples from people with systemic sclerosis to healthy volunteers.

This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.

This research study uses special lab-grown stem cells to understand how systemic sclerosis (a disease that hardens skin and organs) develops and progresses. By studying cells from patients with different types of systemic sclerosis and healthy relatives, researchers hope to find new ways to treat or prevent the disease.

This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.

This study tests whether the medicine clopidogrel can lower the chance of developing systemic sclerosis in adults who have certain blood antibodies and symptoms that suggest higher risk. If you qualify, you would take clopidogrel for the study to see whether it delays or prevents the disease.

This study follows adults with systemic scleroderma (also called scleroderma) to better understand the condition over time. You may be included if you meet specific diagnosis and blood-test requirements and can give informed consent.